Home Biological studies of samarium-153 bleomycin complex in human breast cancer murine xenografts for therapeutic applications
Article
Licensed
Unlicensed Requires Authentication

Biological studies of samarium-153 bleomycin complex in human breast cancer murine xenografts for therapeutic applications

  • A. Bahrami-Samani , M. Ghannadi-Maragheh , A. R. Jalilian and M. Mazidi
Published/Copyright: April 16, 2010

Abstract

In this work, a potential therapeutic DNA targeting agent, 153Sm-bleomycin complex ( 153Sm-BLM), was developed and the tumor accumulation studies were performed using single photon emission computed tomography (SPECT) and scarification studies. 153Sm-BLM was prepared at optimized conditions (room temperature, 4−8 h, 0.1 mg bleomycin for 740−3700 MBq 153SmCl3, radiochemical purity over 98%, HPLC, specific activityߙ=ߙ55 TBq/mmol). 153Sm-BLM was administered into human breast cancer murine xenografts and the biodistribution and imaging studies were performed up to 48 h. 153Sm-BLM demonstrated superior tumor accumulation properties in contrast with the other radiolabeled bleomycins with tumor: blood ratios of 41, 72 and 182 at 4, 24 and 48 h, respectively, and tumor: muscle ratios of 23, 33 and >1490 at 4, 24 and 48 h, respectively, while administered intravenously. The SPECT images also demonstrated the obvious tumor uptake at the chest region of the breast-tumor bearing mice. These initial experiments demonstrate significant accumulation of 153Sm-BLM in tumor tissues.


* Correspondence address: Radiopharmaceutical Research & Development Laboratory (RRDL), Nuclear Science and Tecnology Research Institute (, 14395-836, Tehran, Iran,

Published Online: 2010-04-16
Published in Print: 2010-04

© by Oldenbourg Wissenschaftsverlag, München, Germany

Downloaded on 18.9.2025 from https://www.degruyterbrill.com/document/doi/10.1524/ract.2010.1713/html
Scroll to top button